-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EO-2463 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EO-2463 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EO-2463 in Marginal Zone B-cell Lymphoma Drug Details: EO-2463 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VE-303 in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VE-303 in Clostridioides difficile Infections (Clostridium difficile Associated Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VE-303 in Clostridioides difficile Infections (Clostridium...
-
Product Insights
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drugs In Development, 2023’, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Periodontal Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Periodontal Disease - Drugs In Development, 2023’, provides an overview of the Periodontal Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Periodontal Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VE-800 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VE-800 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VE-800 in Solid Tumor Drug Details: VE-800 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VE-800 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VE-800 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VE-800 in Gastric Cancer Drug Details: VE-800 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VE-800 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VE-800 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VE-800 in Metastatic Melanoma Drug Details: VE-800 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VE-800 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VE-800 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VE-800 in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VE-800 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VE-800 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VE-800 in Metastatic Colorectal Cancer Drug Details: VE-800 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MET-4 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MET-4 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MET-4 in Head And Neck Squamous Cell...